Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 10, 2016, Pages 1435-1448

  Epstein, Murray ^a   Pitt, Bertram ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

chronic kidney disease; congestive heart failure; Hyperkalemia; patiromer; potassium; renin angiotensin aldosterone system

Indexed keywords

BICARBONATE; CALCIUM; DIURETIC AGENT; MAGNESIUM; PATIROMER; POTASSIUM; SODIUM; SODIUM ZIRCONIUM CYCLOSILICATE; SORBITOL; POLYMER;

ABNORMAL LABORATORY RESULT; ALBUMINURIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES; FLATULENCE; GASTROINTESTINAL ABSORPTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MEAN ARTERIAL PRESSURE; META ANALYSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SODIUM BLOOD LEVEL; SODIUM LOAD; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; VOMITING; BLOOD; HEART FAILURE; HEMODIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

HEART FAILURE; HUMANS; HYPERKALEMIA; HYPERTENSION; POLYMERS; POTASSIUM; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84975292114     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1190333     Document Type: Article

References (85)

1. P.Elliott, A.Dyer, R.Stamler The INTERSALT study: results for 24 hour sodium and potassium, by age and sex. J Hum Hypertens. 1989;3:323–330.
2. M.Epstein, M.D.Lifschitz. The unappreciated role of extrarenal and gut sensors in modulating renal potassium handling: inplications for diagnosis of dyskalemias, and interpreting clinical trials. Kidney Int Suppl. 2016;6(April):7–15.•• A recent and comprehensive review of the integrated mechanisms controlling the maintenance of potassium homeostasis. Knowledge imparted by this update of potassium homeostasis hopefully will facilitate the clinical management of hyperkalemia in patients with chronic and recurrent hyperkalemia.
3. G.Giebisch, R.Krapf, C.Wagner. Renal and extrarenal regulation of potassium. Kidney Int. 2007 June 13;72(4):397–410.
4. B.F.Palmer. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015 June 5;10(6):1050–1060.
5. W.Wang. Regulation of renal K transport by dietary K intake. Annu Rev Physiol. 2004;66:547–569. PubMed PMID: 14977413
6. B.F.Palmer. Hyperkalemia in predialysis patients. Clin J Am Soc Nephrol. 2012 Aug;7(8):1201–1202. PubMed PMID: 22773593.
7. C.Bastl, J.P.Hayslett, H.J.Binder. Increased large intestinal secretion of potassium in renal insufficiency. Kidney Int. 1977;12(1):9–16.
8. C.P.HayesJr, M.E.McLeod, R.R.Robinson. An extravenal mechan- ism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207–216.
9. R.S.Martin, S.Panese, M.Virginillo, et al. Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis. 1986;8(2):105–110.
10. G.I.Sandle, M.Hunter. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM. 2009;103(2):85–89.
11. T.Mathialahan, K.A.Maclennan, L.N.Sandle, et al. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol. 2005;206(1):46–51.
12. C.P.Kovesdy. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10:653–662.
13. I.Lazrich, G.L.Bakris. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333–339.
14. P.A.Sarafidis, R.Blacklock, E.Wood, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7:1234–1241.• An important study that identifies all of the factors known to interfere in potassium homeostasis simultaneously present in a population of CKD patients treated in an advanced CKD (low-clearance clinic).
15. N.Jain, S.Kotla, B.B.Little, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510–1513.
16. L.M.Einhorn, M.Zhan, V.D.Hsu, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156–1162.
17. M.A.Perazella, R.L.Mahnensmith. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646–656.
18. M.R.Weir, M.Rolfe. Potassium homeostasis and renin-angiotensin aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531–548.
19. M.Epstein. Hyperkalemia: current concepts and emerging therapeutic options. Kidney Int Suppl. 2016;6:1–2.
20. M.Epstein. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Lancet Diabetes Endocrinol. 2015;3:993–1003.•• A comprehensive review of the pathophysiology and clinical features of cardiovascular disease in patients with chronic kidney disease. It emphasizes that RAAS-inhibitor-induced and MR antagonist-induced hyperkalemia constitute a major constraint to implementation of guidelines in patients with chronic heart failure, chronic kidney disease, and diabetes mellitus.
21. C.M.Ferrario, W.B.Strawn. Role of the renin-angiotensin-aldosterone system and pro-inflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121–128.
22. V.J.Dzau, E.M.Antman, H.R.Black, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850–2870.
23. F.Shearer, C.C.Lang, A.D.Struthers. Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther. 2013;94:459–467.
24. T.W.Hsu, J.S.Liu, S.C.Hung, et al. Renoprotective effect of renin angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174:347–354.
25. C.W.Yancy, M.Jessup, B.Bozkurt, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
26. J.J.McMurray, S.Adamopoulos, S.D.Anker, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
27. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
28. L.A.Inker, B.C.Astor, C.H.Fox, et al. KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63:713–735.
29. T.Yildirim, M.Arici, S.Piskinpasa, et al. Major barriers against renin angiotensin- aldosterone system blocker use in chronic kidney disease stages 3–5 in clinical practice: a safety concern? Ren Fail. 2012;34:1095–1099.
30. K.B.Shah, K.Rao, R.Sawyer, et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845–849.
31. B.Bozkurt, M.D.Agoston, A.A.Knowlton. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211–214.
32. M.J.Krantz, A.V.Ambardekar, L.Kaltenbach, et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines – Heart Failure). Am J Cardiol. 2011;107:1818–1823.
33. N.M.Albert, C.W.Yancy, L.Liang, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658–1665.
34. A.N.Rassi, M.A.Cavender, G.C.Fonarow, et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013;61:35–40.
35. A.P.Maggioni, S.D.Anker, U.Dahlström, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–1184.
36. L.S.Weisberg. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246–3251.
37. M.Epstein, N.L.Reaven, S.E.Funk, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin aldosterone system inhibitors. Am J Manag Care. 2015;21(11 suppl):S212–S220.•• A recent comprehensive ‘big-data analytics’ study of a large database study delineating the role of RAASi-induced hyperkalemia in disrupting the utilization of guideline-mandated RAASi treatment. An important message is that patients who were on submaximum doses, or who discontinued RAASi, had worse cardiorenal outcomes and higher mortality than patients on maximum doses did.
38. F.M.Sacks, L.P.Svetkey, W.M.Vollmer, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001;344:3–10. doi:10.1056/NEJM200101043440101.
39. J.Tamargo, J.Segura, L.M.Ruilope. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15(5):605–621.
40. KAYEXALATE Sodium Polystyrene Sufonate Cation-Exchange Resin: prescribing Information Bridgewater, New Jersey: sanofi-aventis US, LLC; 2010. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186845.htm
41. R.B.Flinn, J.P.Merrill, W.R.Welzant. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol. N Engl J Med. 1961;264(3):111–115. PubMed PMID: 13700297.
42. L.Scherr, D.A.Ogden, A.W.Mead, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264(3):115–119. PubMed PMID: 13747532
43. R.H.Sterns, M.Rojas, P.Bernstein, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010 May 1;21(5):733–735.•• Critical review of the efficacy and safety of sodium polystyrene sulfonate (SPS), emphasizing the potential harm of SPS.
44. J.Batterink, J.Lin, S.H.Au-Yeung, et al. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. Can J Hosp Pharm. 2015 Jul–Aug;68(4):296–303. PubMed PMID: 26327703. Pubmed Central PMCID: PMC4552230.
45. L.LePage, A.C.Dufour, D.JD, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2136–2142.
46. S.C.Abraham, B.S.Bhagavan, L.A.Lee, et al. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol. 2001;25(5):637–644. PubMed PMID: 11342776.
47. C.E.McGowan, S.Saha, G.Chu, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102(5):493–497. PubMed PMID: 19373153. Pubmed Central PMCID: PMC3638814.
48. A.Thomas, B.R.James, D.Landsberg. Colonic necrosis due to oral kayexalate in a critically-ill patient. Am J Med Sci. 2009 Apr;337(4):305–306. PubMed PMID: 19365182.
49. L.Li, S.Harrison, M.J.Cope, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed crosslinked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016 Feb 7:1–10. pii: 1074248416629549. [Epub ahead of print].•• Seminal review of the pharmacology and mechanism of action of patiromer.
50. J.M.Buysse, I.Z.Huang, B.Pitt. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol. 2011 [[cited 2012 Jan1]];8(1):17–28.
51. M.R.Weir, G.L.Bakris, D.A.Bushinsky, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211–221. PubMed PMID: 25415805.•• OPAL-HK constitutes one of two major studies demonstrating the safety and efficacy of patiromer for the management of hyperkalemia.
52. VELTESSA (patiromer) for oral suspension. 2015 Full Prescribing Information Redwood City, California: Relypsa, Inc. [updated 2015 Oct; cited 2015 Dec 2]. Available from: http://www.relypsa.com/veltassa/prescribing-information/
53. Food and Drug Administration Department of Health and Human Services. Electronic code of federal regulations. Sorbitol. 42 Federal register 14653. Washington (DC): US Government Publishing Office; 1984. Codified at 21 CFR §184.
54. G.Bakris, M.Weir, M.Epstein. Letter in response to cardiorenal syndromes [CRS]: advances in determining diagnosis, prognosis, and therapy. J Cardiovasc Dis Diagn. 2016;4:2.
55. D.A.Bushinsky, D.M.Spiegel, W.Benton, et al. Effect of the potassium adults (abstract SO008). ERA meeting; 2016 May; Vienna. Available from: http://www.abstracts2view.com/era/view.php?nu=ERA16L1_988.
56. D.Bushinsky, D.Spiegel, C.Gross, et al. Effect of patiromer on urine calcium and phosphate excretion in healthy adults. Am J Kidney Dis. 2016;67(5):A30.
57. D.A.Bushinsky, G.H.Williams, B.Pitt, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427–1433. PubMed PMID: 26376130. Epub 2015 Sept 16. doi:10.1038/ki.2015.270.
58. G.L.Bakris, B.Pitt, M.R.Weir, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015 Jul 14;314(2):151–161. PubMed PMID: 26172895.•• Second of two major articles demonstrating the clinical utility and safety of the new polymeric potassium binder patiromer for management of hyperkalemia. This study also demonstrated that chronic treatment with patiromer lowered serum potassium sufficiently for periods exceeding 52 weeks, thereby preventing down titrations/discontinuations of RAASi therapy due to hyperkalemia.
59. B.Pitt, S.D.Anker, D.A.Bushinsky, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–828. PubMed PMID: 21208974. Pubmed Central PMCID: PMC3069389.
60. M.R.Weir, G.L.Bakris, C.Gross, et al. Patiromer decreased aldosterone, urine albumin/creatinine ratio, and systolic blood pressure in pts with chronic kidney disease and hyperkealm on RAAS inhibitors. Results from OPAL-HK. Presented as a late-breaker poster at the 2015 American Society of Hypertension Annual Meeting, 2015 May 18; New York, NY.
61. B.Pitt, G.L.Bakris, D.A.Bushinsky, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–1065. PubMed PMID: 26459796.
62. M.R.Weir, D.A.Bushinsky, M.R.Mayo, et al., editors. Patiromer lowers serum K+ and prevents recurrent hyperkalemia in CKD patients > 65 years of age on RAAS inhibitors. San Diego, CA: Journal of the American Society of Nephrology; 2015 [cited 2015 Nov3–8]. file:///C:/Users/slee/Downloads/KW15Abstracts.pdf.
63. M.R.Weir, M.R.Mayo, D.Garza, et al., editors. Chronic diuretic therapy does not impair the effectiveness of patiromer in hyperkalemic patients with CKD. San Diego (CA): Journal of the American Society of Nephrology; 2015. file:///C:/Users/slee/Downloads/KW15Abstracts.pdf.
64. Relypsa announces FDA approval of veltassa(TM) (patiromer) for oral suspension for the treatment of hyperkalemia Redwood City, California: Relypsa, Inc.; 2015 [updated Oct25; cited 2015 Dec 2]. Available from: http://globenewswire.com/news-release/2015/10/22/778801/0/en/RELYPSA-ANNOUNCES-FDA-APPROVAL-OF-VELTASSA-TM-PATIROMER-FOR-ORAL-SUSPENSION-FOR-THE-TREATMENT-OF-HYPERKALEMIA.html
65. E.Pasani, R.Aquilani, C.Testa, et al. Pathogenic gut flora in patients with chronic heart failure CME. JCHF. 2016;4(3):220–227.
66. + selective ion trap. PLoS One. 2014;9:e114686.
67. S.D.Anker, M.Kosiborod, F.Zannad, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17:1050–1056.
68. J.A.Tumlin, M.Kosiborod, P.E.Pergola, et al. SA-PO1101 long-term (52-week) efficacy and safety of ZS-9 in the treatment of hyperkalemia: interim results from a phase 3 open-label, multi-center, multi-dose maintenance study. JASN. 2015;26:B6. Abstract Edition: file:///C:/Users/slee/Downloads/KW15Abstracts.pdf
69. S.F.Phillips. Giller J: the contribution of the colon to electrolyte and water conservation in man. J Lab Clin Med. 1973;81:733–746.
70. F.Bronner, D.Pansu. Nutritional aspects of calcium absorption. J Nutr. 1999;129:9–12.
71. J.W.Coburn, M.H.Koppel, A.S.Brickman, et al. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int. 1973;3:264–272 [PubMed: 4600294].
72. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; R.ACRoss, T.CLTaylor, et al., editors. Dietary reference intakes for calcium and vitamin D. Washington (DC): National Academies Press; 2011.
73. P.McCullough, J.A.Tumlin, H.Szerlip, et al. Cardiorenal Syndromes [CRS]: advances in determining diagnosis, prognosis, and therapy. J Cardiovasc Dis Diagn. 2015;3:221. doi:10.4172/2329-9517.1000221.
74. B.M.Egan, Y.Zhao, R.N.Axon, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–1058.
75. W.B.White, J.R.Turner, D.A.Sica, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014;8:743–757.
76. B.Williams, T.M.MacDonald, S.Morant, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068.
77. J.Rosa, P.Widimský, P.Waldauf, et al. Role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016;67:397–403.
78. M.Epstein, M.Mayo, D.Garza, et al. Patiromer controls hyperkalemia in resistant hypertensive patients on RAASi, with diabetic kidney disease. Circulation. 2015;132(Suppl 3):A14271.
79. B.Pitt, F.Zannad, W.J.Remme, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–717.
80. B.Pitt, W.Remme, F.Zannad, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
81. F.Zannad, J.J.McMurray, H.Krum, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
82. P.T.O’Gara, F.G.Kushner, D.D.Ascheim, et al. 2013 accf/aha guideline for the management of st-elevation myocardial infarction: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines: developed in collaboration with the american college of emergency physicians and society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E1–27.
83. S.Shore, T.M.Maddox, F.Tang, et al. Gap between clinical guidelines and practice: the case of aldosterone-antagonists in patients with myocardial infarction. Int J Cardiol. 2014;172:e151–153.
84. M.A.Chamsi-Pasha, M.Dupont, W.A.Al Jaroudi, et al. Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. J Card Fail. 2014;20:229–235.
85. A.Struthers, H.Krum, G.H.Williams. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153–158.